339 top medical experts on Diffuse Scleroderma across 50 countries and 25 U.S. states, including 206 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Diffuse Scleroderma: A rapid onset form of systemic scleroderma with progressive widespread skin thickening over the arms, the legs and the trunk, resulting in stiffness and disability.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Systemic Scleroderma (5,099).
  4. Clinical Trials ClinicalTrials.gov : at least 452 including 23 Active, 212 Completed, 87 Recruiting


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Khanna, Dinesh   Internal Medicine   ClinicalTrials.gov Google Publications
    Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Relevant US NIH Grant Funding: $642,261 over the last 5 years
    Medical school: Other (MD, 1996)
    Medicare Accepted
    Disclosed payments in 2021 from 41 biomedical companies, totalling $56,923.19, including $13,951.21 from  Boehringer Ingelheim International GmbH
    Subjects: Scleroderma, Diffuse; Skin Diseases; Skin; Lung Diseases, Interstitial; Immunosuppressive Agents; Scleroderma, Systemic
    Categories: Drug Therapy; Therapeutic Use; Genetics; Metabolism; Complications; Diagnosis
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. (2020)

  2. Gordon, Jessica K   Internal Medicine   Google Publications
    Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Scleroderma, Diffuse; Skin; Lung; Lung Diseases, Interstitial; Piperazines; Protein Kinase Inhibitors
    Categories: Therapeutic Use; Metabolism; Drug Therapy; Pathology; Blood; Diagnosis
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)

  3. Furst, Daniel E   Rheumatology  ClinicalTrials.gov Google Publications
    Division of Rheumatology, UCLA, Los Angeles, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 89/100
    Disclosed payments in 2021 from 107 biomedical companies, totalling $13,857.98, including $6,157.14 from  F. Hoffmann-La Roche AG
    Subjects: Scleroderma, Diffuse; Skin Diseases; Lung Diseases, Interstitial; Antirheumatic Agents; Gastrointestinal Diseases; Musculoskeletal Diseases
    Categories: Complications; Drug Therapy; Therapeutic Use; Methods; Diagnosis; Etiology
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. (2016)

  4. Mayes, Maureen D   Rheumatology  ClinicalTrials.gov Google Publications
    Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Eastern Virginia Medical School (MD, 1976)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 63/100
    Disclosed payments in 2021 from 11 biomedical companies, totalling $4,052.65, including $3,969.53 from  Boehringer Ingelheim International GmbH
    Subjects: Scleroderma, Diffuse; Skin Diseases; Scleroderma, Limited; Severity of Illness Index; Lung Diseases, Interstitial; Musculoskeletal Diseases
    Categories: Genetics; Complications; Blood; Methods; Therapeutic Use; Diagnosis
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)

  5. Spiera, Robert F   Rheumatology   ClinicalTrials.gov Google Publications
    Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Yale University School of Medicine (MD, 1989)
    Medicare Accepted
    Disclosed payments in 2021 from 4 biomedical companies, totalling $3,033.42, including $1,600 from  AbbVie Inc.
    Subjects: Scleroderma, Diffuse; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin; Hypertension, Pulmonary
    Categories: Therapeutic Use; Metabolism; Drug Therapy; Blood; Drug Effects; Pathology
    Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. (2011)
    Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. (2018)

  6. Chung, Lorinda S   Rheumatology   ClinicalTrials.gov Google Publications
    Stanford University School of Medicine and Veterans Administration Palo Alto Health Care System, Palo Alto, California. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Ohio State University College of Medicine (MD, 2000)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 65/100
    Disclosed payments in 2021 from 2 biomedical companies, totalling $1,000, including $1,000 from  Genentech, Inc.
    Subjects: Scleroderma, Diffuse; Scleroderma, Limited; Abatacept; Immunosuppressive Agents; Lung; Lung Diseases, Interstitial
    Categories: Therapeutic Use; Physiopathology; Diagnostic Imaging; Complications; Drug Therapy; Blood
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). (2017)

  7. Simms, Robert W   Rheumatology  ClinicalTrials.gov Google Publications
    Dartmouth College Geisel School of Medicine, Hanover, New Hampshire.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: University of Rochester School of Medicine and Dentistry (MD, 1980)
    Medicare Accepted
    Subjects: Scleroderma, Diffuse; Scleroderma, Limited; Antirheumatic Agents; Cytokines; Lung Diseases, Interstitial; Skin
    Categories: Therapeutic Use; Drug Therapy; Physiopathology; Therapy; Immunology; Metabolism
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. (2016)

  8. Bernstein, Elana J   Rheumatology   Google Publications
    Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 6 biomedical companies, totalling $10,913.74, including $10,896.42 from  Boehringer Ingelheim Pharmaceuticals, Inc.
    Subjects: Scleroderma, Diffuse; Lung; Hypertension, Pulmonary; Lung Diseases, Interstitial; Abatacept; Adaptive Immunity
    Categories: Metabolism; Pathology; Therapeutic Use; Diagnosis; Genetics; Physiopathology
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)

  9. Hant, Faye N   Rheumatology   Google Publications
    Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 4 biomedical companies, totalling $60.25, including $60.25 from  Amgen Inc.
    Subjects: Scleroderma, Diffuse; Lung Diseases, Interstitial; Skin; Abatacept; Adaptive Immunity; Antigens, CD
    Categories: Metabolism; Complications; Pathology; Diagnosis; Genetics; Therapeutic Use
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)

  10. Assassi, Shervin   Rheumatology   ClinicalTrials.gov Google Publications
    Department of Medicine, University of Texas Health Science Center, Houston, TX, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Relevant US NIH Grant Funding: $1,357,551 over the last 5 years
    Medical school: Other (MD, 1999)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 63/100
    Disclosed payments in 2021 from 17 biomedical companies, totalling $20,466.01, including $8,120 from  Boehringer Ingelheim Pharmaceuticals, Inc.
    Subjects: Scleroderma, Diffuse; Lung Diseases, Interstitial; Adaptive Immunity; Adaptor Proteins, Signal Transducing; Antirheumatic Agents; Gastric Antral Vascular Ectasia
    Categories: Genetics; Pathology; Complications; Diagnosis; Therapeutic Use; Drug Therapy
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)
    The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. (2016)

  11. Shah, Ami A   Rheumatology   Google Publications
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Subjects: Scleroderma, Diffuse; Autoantibodies; Immunosuppressive Agents; Glomerulonephritis; Lung Diseases, Interstitial; Neoplasms
    Categories: Immunology; Complications; Therapeutic Use; Drug Therapy; Etiology; Genetics
    Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. (2021)
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)

  12. Shanmugam, Victoria K   Rheumatology   ClinicalTrials.gov Google Publications
    Department of Medicine, George Washington University, Washington, DC, USA.
    Physician  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100
    Subjects: Scleroderma, Diffuse; Lung Diseases, Interstitial; Adaptive Immunity; Hemoptysis; Immunity, Innate; Immunosuppressive Agents
    Categories: Diagnostic Imaging; Genetics; Diagnosis; Pathology; Complications; Drug Therapy
    Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. (2020)
    Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. (2021)

  13. Shah, Sanjiv J   Cardiovascular Disease  Google Publications
    Northwestern University, Chicago, Illinois. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 86.9/100
    Disclosed payments in 2021 from 27 biomedical companies, totalling $51,766.6, including $14,250 from  Novo Nordisk AS
    Subjects: Scleroderma, Diffuse; Hematopoietic Stem Cell Transplantation; Scleroderma, Limited; Peripheral Blood Stem Cell Transplantation; Cause of Death; Heart Failure
    Categories: Mortality; Methods; Therapy; Genetics; Administration & Dosage; Drug Therapy
    Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. (2013)
    Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. (2017)

  14. Schiopu, Elena   Rheumatology  Google Publications
    Division of Rheumatology, Department of Internal Medicine, Michigan Medicine University Hospitals, Ann Arbor, Michigan, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1997)
    Medicare Accepted
    Disclosed payments in 2021 from 21 biomedical companies, totalling $12,701.72, including $5,065.56 from  Novartis Pharmaceuticals Corporation
    Subjects: Scleroderma, Diffuse; Abatacept; Antirheumatic Agents; Dermis; Endothelial Cells; Enzyme Activators
    Categories: Metabolism; Therapeutic Use; Administration & Dosage; Drug Therapy; Genetics; Pathology
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. (2020)

  15. Burt, Richard K   Clinical & Laboratory Immunology   ClinicalTrials.gov Google Publications
    Division of Immunotherapy, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Top Hospital
    Physician 
    Subjects: Hematopoietic Stem Cell Transplantation; Scleroderma, Diffuse; Peripheral Blood Stem Cell Transplantation; Scleroderma, Limited; Cause of Death; Heart Failure
    Categories: Mortality; Methods; Therapy; Administration & Dosage; Drug Therapy
    Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. (2013)
    Cardiac assessment before stem cell transplantation for systemic sclerosis. (2014)

  16. Wigley, Fredrick M   Rheumatology  ClinicalTrials.gov Google Publications
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Top Hospital
    Physician  Highly Published  Case Reports 
    Subjects: Scleroderma, Diffuse; Autoantibodies; Glomerulonephritis; Immunosuppressive Agents; Peripheral Nervous System Diseases; Skin
    Categories: Complications; Immunology; Etiology; Therapeutic Use; Blood; Diagnosis
    Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. (2018)
    Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. (2011)

  17. Denton, Christopher P     ClinicalTrials.gov Google Publications
    Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, UK .
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Scleroderma, Diffuse; Scleroderma, Limited; Immunosuppressive Agents; Scleroderma, Systemic; Skin; Severity of Illness Index
    Categories: Therapeutic Use; Drug Therapy; Mortality; Pathology; Blood; Genetics
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. (2020)
    Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. (2020)

  18. Hummers, Laura K   Rheumatology  Google Publications
    Johns Hopkins University, Baltimore, Maryland. Top Hospital
    Physician  Highly Cited  Highly Published 
    Disclosed payments in 2021 from 7 biomedical companies, totalling $6,548.62, including $3,098.62 from  Boehringer Ingelheim International GmbH
    Subjects: Scleroderma, Diffuse; Autoantibodies; Glomerulonephritis; Immunosuppressive Agents; Neoplasms; Peripheral Nervous System Diseases
    Categories: Complications; Physiopathology; Immunology; Etiology; Therapeutic Use; Drug Therapy
    Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. (2021)
    Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. (2018)

  19. Jimenez, Sergio A   Rheumatology  Google Publications
    Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University. Philadelphia, PA 19107, USA.
    Physician  Clinical Trial 
    Relevant US NIH Grant Funding: $788,965 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Subjects: Scleroderma, Diffuse; Skin; Immunosuppressive Agents; Mycophenolic Acid; Aniline Compounds; Cell Adhesion Molecules
    Categories: Metabolism; Pharmacology; Drug Therapy; Therapeutic Use; Antagonists & Inhibitors; Drug Effects
    A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. (2012)
    Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. (2020)

  20. Crow, Mary K   Rheumatology   Google Publications
    Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY, 10021, USA. .
    Physician  Clinical Trial 
    Disclosed payments in 2021 from 6 biomedical companies, totalling $22,376.25, including $13,986.25 from  AstraZeneca UK Limited
    Subjects: Pyrimidines; Scleroderma, Diffuse; Piperazines; Protein Kinase Inhibitors; Benzamides; Dermatologic Agents
    Categories: Therapeutic Use; Drug Therapy; Drug Effects
    Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. (2011)
    Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. (2015)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);